{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:15:36Z","timestamp":1793312136559,"version":"4.5.0"},"reference-count":261,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115948","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:49:27Z","timestamp":1764722967000},"page":"115948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Tumor microenvironment and immunometabolic reprogramming in pancreatic ductal adenocarcinoma: Barriers and breakthroughs in immunotherapy"],"prefix":"10.1016","volume":"169","author":[{"given":"Liming","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kean Chang","family":"Phang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0010","first-page":"1729","volume":"186","author":"Halbrook","year":"2023","journal-title":"Pancreatic Cancer: Adv. Challenges Cell"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0020","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41419-024-06930-0","article-title":"Emerging mechanisms and promising approaches in pancreatic cancer metabolism","volume":"15","author":"Wu","year":"2024","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112681","article-title":"Integrated spatial omics of metabolic reprogramming and the tumor microenvironment in pancreatic cancer","volume":"28","author":"Wu","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.intimp.2025.115948_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0035","article-title":"Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization","volume":"16","author":"Katopodi","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00018-020-03581-0","article-title":"Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance","volume":"78","author":"Wei","year":"2020","journal-title":"Cell Mol. Life Sci. CMLS."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0045","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for Cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0050","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/cancers12082274","article-title":"Mechanisms of T-cell exhaustion in pancreatic Cancer","volume":"12","author":"Saka","year":"2020","journal-title":"Cancers"},{"issue":"7806","key":"10.1016\/j.intimp.2025.115948_bb0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/1535-7163.MCT-18-0850","article-title":"TGF\u03b2 blockade augments PD-1 inhibition to promote T-cell-mediated regression of pancreatic Cancer","volume":"18","author":"Principe","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.115948_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.839893","article-title":"Type 1 T helper cell-based molecular subtypes and signature are associated with clinical outcome in pancreatic ductal adenocarcinoma","volume":"10","author":"Wei","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41416-022-02056-2","article-title":"Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils","volume":"128","author":"Jacenik","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12957-021-02420-1","article-title":"The prognostic value of intratumoral and peritumoral tumor-infiltrating FoxP3+Treg cells in of pancreatic adenocarcinoma: a meta-analysis","volume":"19","author":"Hu","year":"2021","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0080","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1038\/s41467-023-38578-3","article-title":"Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.115948_bb0085","series-title":"Regulatory T Cells in Cancer. Annu Rev Cancer Biol","first-page":"459","volume":"4","author":"Plitas","year":"2020"},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115948_bb0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2019.00496","article-title":"Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic Cancer patients","volume":"10","author":"Lim","year":"2019","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2025.115948_bb0100","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0110","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1158\/2326-6066.CIR-21-0946","article-title":"Systemic alterations in Type-2 conventional dendritic cells Lead to impaired tumor immunity in pancreatic Cancer","volume":"11","author":"James","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"10.1016\/j.intimp.2025.115948_bb0115","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/cancers14051216","article-title":"Clinical significance of tumor-infiltrating conventional and plasmacytoid dendritic cells in pancreatic ductal adenocarcinoma","volume":"14","author":"Plesca","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccell.2020.02.008","article-title":"Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic Cancer","volume":"37","author":"Hegde","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000772","article-title":"Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model","volume":"8","author":"Lau","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0130","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/ijms24032858","article-title":"Macrophage repolarization as a therapeutic strategy for osteosarcoma","volume":"24","author":"Anand","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2025.115948_bb0135","doi-asserted-by":"crossref","first-page":"1679514","DOI":"10.3389\/fcimb.2025.1679514","article-title":"Interplay of autophagy and Th1\/Th2-mediated macrophage polarization in host-pathogen dynamics","volume":"15","author":"Shoeran","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41419-023-06032-3","article-title":"The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2025.115948_bb0145","article-title":"Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.intimp.2025.115948_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.605619","article-title":"Tumor-derived myeloid cell Chemoattractants and T cell exclusion in pancreatic Cancer","volume":"11","author":"Vonderheide","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13107","article-title":"IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients","volume":"94","author":"Sharma","year":"2021","journal-title":"Scand. J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115948_bb0165","article-title":"Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer","volume":"18;25(11):105317","author":"Sarhan","year":"2022","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0170","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0175","first-page":"665","article-title":"CXCL10 and CCL21 promote migration of pancreatic Cancer cells toward sensory neurons and neural Remodeling in Tumors in mice","volume":"159","author":"Hirth","year":"2020","journal-title":"Associated With Pain in Patients. Gastroenterology."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0180","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41423-020-00613-4","article-title":"Tumor-associated myeloid cells: diversity and therapeutic targeting","volume":"18","author":"Mantovani","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2025.115948_bb0185","article-title":"Deterministic reprogramming of neutrophils within tumors","volume":"12;383(6679):eadf6493","author":"Ng","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.115948_bb0190","article-title":"Neutralization of NET-associated human ARG1 enhances cancer immunotherapy","volume":"15;15(687)","author":"Can\u00e8","year":"2023","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb0195","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1111\/jcmm.16555","article-title":"Neutrophil extracellular DNA traps promote pancreatic cancer cells migration and invasion by activating EGFR\/ERK pathway","volume":"25","author":"Jin","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0200","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1136\/gutjnl-2022-328697","article-title":"Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas","volume":"72","author":"Kinker","year":"2023","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/2159-8290.CD-15-0843","article-title":"IL35-producing B cells promote the development of pancreatic neoplasia","volume":"6","author":"Pylayeva-Gupta","year":"2016","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/2326-6066.CIR-19-0349","article-title":"B cell-derived IL35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic Cancer","volume":"8","author":"Mirlekar","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"7931","key":"10.1016\/j.intimp.2025.115948_bb0215","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","article-title":"STING-induced regulatory B cells compromise NK function in cancer immunity","volume":"610","author":"Li","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115948_bb0220","article-title":"Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity","volume":"12;3(9):100744","author":"Mirlekar","year":"2022","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0225","first-page":"8","article-title":"Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept","volume":"43","author":"Luo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0230","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2019-319912","article-title":"Interleukin-1\u03b2-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression","volume":"70","author":"Takahashi","year":"2021","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0235","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.3390\/ijms24087030","article-title":"Cancer stem cells in pancreatic ductal adenocarcinoma","volume":"24","author":"Bubin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0240","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.714","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0250","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/s41416-022-01927-y","article-title":"ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1\u03b2\/NF-\u03baB\/ESE3 signalling axis","volume":"127","author":"Zhao","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"539","key":"10.1016\/j.intimp.2025.115948_bb0255","article-title":"Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma","volume":"28","author":"Kong","year":"2022","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.intimp.2025.115948_bb0260","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.3390\/cancers14225475","article-title":"Galectins are central mediators of immune escape in pancreatic ductal adenocarcinoma","volume":"14","author":"Jiang","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0265","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-19-0959","article-title":"Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic Cancer","volume":"10","author":"Parker","year":"2020","journal-title":"Cancer Discov."},{"issue":"49","key":"10.1016\/j.intimp.2025.115948_bb0270","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/s41388-024-03183-1","article-title":"Mesenchymal stromal cells as cancer promoters","volume":"43","author":"Antoon","year":"2024","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0275","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.stem.2012.08.013","article-title":"CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNF\u03b1","volume":"11","author":"Ren","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. OncolJ. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb0285","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0290","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0295","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","article-title":"Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic Cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","article-title":"Di. Cancer-Associated Fibroblasts: Lessons from Pancreatic Cancer","volume":"11","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb0305","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.intimp.2025.115948_bb0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic Cancer pathogenesis and therapeutic resistance","volume":"24","author":"Sherman","year":"2023","journal-title":"Annu. Rev. Pathol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0320","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1053\/j.gastro.2017.09.039","article-title":"Interleukin 35 expression correlates with microvessel density in pancreatic ductal adenocarcinoma, recruits monocytes, and promotes growth and angiogenesis of xenograft Tumors in mice","volume":"154","author":"Huang","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189032","article-title":"Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: molecular mechanisms and clinical perspectives","volume":"1879","author":"Xu","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.115948_bb0330","first-page":"1027","article-title":"Future directions in preclinical and translational cancer neuroscience research","volume":"1","author":"Demir","year":"2021","journal-title":"Nat. Can."},{"issue":"5","key":"10.1016\/j.intimp.2025.115948_bb0335","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ccell.2018.10.010","article-title":"\u03b22 adrenergic-Neurotrophin feedforward loop promotes pancreatic Cancer","volume":"34","author":"Renz","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.115948_bb0340","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2024.10.010","article-title":"Biomaterials to regulate tumor extracellular matrix in immunotherapy","volume":"376","author":"Zhang","year":"2024","journal-title":"J. Control Release Off J. Control Release Soc."},{"key":"10.1016\/j.intimp.2025.115948_bb0345","doi-asserted-by":"crossref","first-page":"1340634","DOI":"10.3389\/fimmu.2023.1340634","article-title":"Extracellular matrix remodeling in the tumor immunity","volume":"14","author":"Du","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0350","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1535-7163.MCT-22-0595","article-title":"Interplay between extracellular matrix Remodeling and angiogenesis in tumor ecosystem","volume":"22","author":"Siddhartha","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.intimp.2025.115948_bb0355","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.3390\/cancers14163998","article-title":"The extracellular matrix: a key accomplice of Cancer stem cell migration, metastasis formation, and drug resistance in PDAC","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0360","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-020-0329-1","article-title":"Chemokines: the (un)usual suspects in pancreatic cancer neural invasion","volume":"18","author":"Demir","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0365","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-020-00267-8","article-title":"Targeting chemokines\/chemokine receptors: a promising strategy for enhancing the immunotherapy of pancreatic ductal adenocarcinoma","volume":"5","author":"Gong","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2025.115948_bb0370","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"12;8(1):199","author":"Ju","year":"2024","journal-title":"Npj Precis. Oncol."},{"issue":"20","key":"10.1016\/j.intimp.2025.115948_bb0375","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1158\/1078-0432.CCR-20-1303","article-title":"PD-L1 protein expression on both tumor cells and macrophages are associated with response to neoadjuvant durvalumab with chemotherapy in triple-negative breast Cancer","volume":"26","author":"Ahmed","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0380","doi-asserted-by":"crossref","first-page":"513","DOI":"10.14348\/molcells.2022.2056","article-title":"Current understanding of cytotoxic T lymphocyte Antigen-4 (CTLA-4) Signaling in T-cell biology and disease therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol. Cell"},{"issue":"20","key":"10.1016\/j.intimp.2025.115948_bb0385","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"11","author":"Mao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2025","key":"10.1016\/j.intimp.2025.115948_bb0390","article-title":"Systematic review of Interleukin-35 in endothelial dysfunction: a new target for therapeutic intervention","volume":"12","author":"Li","year":"2025","journal-title":"Mediat. Inflamm."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb0395","article-title":"TGF-\u03b2 Signaling and resistance to Cancer therapy","volume":"30","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0400","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 Signaling in immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0405","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cimb47030179","article-title":"Vascular endothelial growth factor receptors in the vascularization of pancreatic Tumors: implications for prognosis and therapy","volume":"47","author":"Grobbelaar","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.intimp.2025.115948_bb0410","article-title":"Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment","volume":"3;12(1):96","author":"Zhang","year":"2024","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0415","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"15","key":"10.1016\/j.intimp.2025.115948_bb0420","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.3390\/ijms22158068","article-title":"CD39 regulation and functions in T cells","volume":"22","author":"Timperi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0425","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0430","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12175","article-title":"Tissue-derived extracellular vesicles in cancers and non-cancer diseases: present and future","volume":"10","author":"Li","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.intimp.2025.115948_bb0435","article-title":"Human macrophage-engineered vesicles for utilization in ovarian cancer treatment","volume":"12","author":"Schweer","year":"2022","journal-title":"Front. Oncol."},{"issue":"50","key":"10.1016\/j.intimp.2025.115948_bb0440","doi-asserted-by":"crossref","first-page":"46222","DOI":"10.1021\/acsomega.2c04420","article-title":"Dendritic cell membrane-derived nanovesicles for targeted T cell activation","volume":"7","author":"Harvey","year":"2022","journal-title":"ACS Omega"},{"issue":"20","key":"10.1016\/j.intimp.2025.115948_bb0445","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/cells14201616","article-title":"Cisplatin-loaded M1 macrophage-derived vesicles have anti-Cancer activity in osteosarcoma","volume":"14","author":"Anand","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0450","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-022-01671-0","article-title":"Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer","volume":"21","author":"Han","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0455","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","article-title":"Exosomes: key players in cancer and potential therapeutic strategy","volume":"5","author":"Dai","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0460","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.ymthe.2020.11.024","article-title":"M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F2","volume":"29","author":"Yang","year":"2021","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0465","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12488","article-title":"Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-hippo pathway and promoting SPARC secretion from pancreatic stellate cells","volume":"13","author":"Qin","year":"2024","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0470","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0475","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0480","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43046-023-00186-z","article-title":"Mechanisms of HIF-driven immunosuppression in tumour microenvironment","volume":"35","author":"Bandopadhyay","year":"2023","journal-title":"J Egypt Natl Cancer Inst."},{"key":"10.1016\/j.intimp.2025.115948_bb0485","article-title":"Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma","volume":"30;43(1):271","author":"Zhang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0490","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","article-title":"HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies","volume":"11","author":"Zhao","year":"2024","journal-title":"Genes Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0495","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3390\/cancers17111860","article-title":"Bridging immune evasion and vascular dynamics for novel therapeutic Frontiers in hepatocellular carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.intimp.2025.115948_bb0500","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.7150\/thno.95766","article-title":"Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0505","first-page":"24","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0510","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"issue":"19","key":"10.1016\/j.intimp.2025.115948_bb0515","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/cells13191666","article-title":"Beyond Cancer cells: how the tumor microenvironment drives Cancer progression","volume":"13","author":"Sabit","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0520","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","article-title":"Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity","volume":"15","author":"Yan","year":"2022","journal-title":"J. Hematol. OncolJ. Hematol. Oncol."},{"issue":"6487","key":"10.1016\/j.intimp.2025.115948_bb0525","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"10","author":"Faubert","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0530","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","article-title":"The hallmarks of cancer metabolism: still emerging","volume":"34","author":"Pavlova","year":"2022","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.intimp.2025.115948_bb0535","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.tcb.2022.09.009","article-title":"Plasticity of cancer invasion and energy metabolism","volume":"33","author":"Parlani","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0540","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/cancers12010002","article-title":"Metabolic alterations in pancreatic Cancer progression","volume":"12","author":"Vernucci","year":"2020","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.intimp.2025.115948_bb0545","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/0008-5472.CAN-20-3792","article-title":"Targeting glucose metabolism sensitizes pancreatic Cancer to MEK inhibition","volume":"81","author":"Yan","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.115948_bb0550","article-title":"FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis","volume":"3;13(9):765","author":"Cai","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0555","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.gendis.2023.06.017","article-title":"IGF2BPs as novel m6A readers: diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment","volume":"11","author":"Duan","year":"2024","journal-title":"Genes Dis."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0560","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s12094-021-02565-1","article-title":"UCHL3 promotes aerobic glycolysis of pancreatic cancer through upregulating LDHA expression","volume":"23","author":"Fan","year":"2021","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108231","article-title":"Respiratory Supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic Cancer","volume":"33","author":"Hollinshead","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0570","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1038\/s41467-020-18954-z","article-title":"Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells","volume":"11","author":"Valle","year":"2020","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0575","article-title":"Targeting mitochondrial complex I overcomes chemoresistance in high OXPHOS pancreatic Cancer","volume":"1","author":"Masoud","year":"2020","journal-title":"Cell Rep Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108231","article-title":"Respiratory Supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer","volume":"33","author":"Hollinshead","year":"2020","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.intimp.2025.115948_bb0585","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41389-020-0231-2","article-title":"COX6B2 drives metabolic reprogramming toward oxidative phosphorylation to promote metastasis in pancreatic ductal cancer cells","volume":"9","author":"Nie","year":"2020","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55296-3","article-title":"Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner","volume":"9","author":"Shiratori","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0595","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41580-021-00415-0","article-title":"The assembly, regulation and function of the mitochondrial respiratory chain","volume":"23","author":"Vercellino","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0600","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12964-023-01130-3","article-title":"KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion","volume":"21","author":"Sabe","year":"2023","journal-title":"Cell Commun. Signal CCS."},{"issue":"19","key":"10.1016\/j.intimp.2025.115948_bb0605","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1158\/1078-0432.CCR-20-5020","article-title":"PGC1\u03b1-mediated metabolic reprogramming drives the stemness of pancreatic precursor lesions","volume":"27","author":"Nimmakayala","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0610","article-title":"The role of amino acid metabolism alterations in pancreatic cancer: from mechanism to application","volume":"1878","author":"Fu","year":"2023","journal-title":"Biochim. Biophys. Acta BBA \u2013 Rev. Cancer"},{"issue":"7678","key":"10.1016\/j.intimp.2025.115948_bb0615","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature24057","article-title":"Glucose feeds the TCA cycle via circulating lactate","volume":"551","author":"Hui","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0620","first-page":"85","article-title":"Targeting pancreatic cancer metabolic dependencies through glutamine antagonism","volume":"5","author":"Encarnaci\u00f3n-Rosado","year":"2024","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0625","first-page":"100","article-title":"Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma","volume":"5","author":"Recouvreux","year":"2024","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0630","first-page":"27","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun. Lond. Engl."},{"key":"10.1016\/j.intimp.2025.115948_bb0635","article-title":"Key events in cancer: dysregulation of SREBPs","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"6427","key":"10.1016\/j.intimp.2025.115948_bb0640","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.aav0173","article-title":"Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation","volume":"363","author":"Lee","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0645","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-021-03613-y","article-title":"Lipid peroxidation and the subsequent cell death transmitting from ferroptotic cells to neighboring cells","volume":"12","author":"Nishizawa","year":"2021","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0650","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","article-title":"Greasing the wheels of the Cancer machine: the role of lipid metabolism in Cancer","volume":"31","author":"Snaebjornsson","year":"2020","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb0655","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s12276-023-01079-w","article-title":"Functional significance of cholesterol metabolism in cancer: from threat to treatment","volume":"55","author":"Xiao","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0660","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s42003-021-02508-0","article-title":"LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma","volume":"4","author":"Acier","year":"2021","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0665","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s12253-019-00698-x","article-title":"Total serum cholesterol and pancreatic Cancer risk: what is the link?","volume":"26","author":"Mormile","year":"2020","journal-title":"Pathol. Oncol. Res. POR."},{"issue":"28","key":"10.1016\/j.intimp.2025.115948_bb0670","article-title":"Aberrant cholesterol metabolism and Wnt\/\u03b2-catenin Signaling coalesce via Frizzled5 in supporting Cancer growth","volume":"9","author":"Zheng","year":"2022","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb0675","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.31557\/APJCP.2023.24.12.4103","article-title":"The inhibition mechanism of pancreatic ductal adenocarcinoma via LXR receptors: a multifaceted approach integrating molecular docking, molecular dynamics and post-MD inter-molecular contact analysis","volume":"24","author":"Agar","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0680","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","article-title":"Cholesterol pathway inhibition induces TGF-\u03b2 Signaling to promote basal differentiation in pancreatic Cancer","volume":"38","author":"Gabitova-Cornell","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb0685","article-title":"Fundamentals of T cell metabolism and strategies to enhance Cancer immunotherapy","volume":"18","author":"Rangel Rivera","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0690","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming","volume":"14","author":"Wu","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0695","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.gendis.2022.07.009","article-title":"Functional crosstalk and regulation of natural killer cells in tumor microenvironment: significance and potential therapeutic strategies","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis."},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0700","article-title":"Metabolic regulation of dendritic cell activation and immune function during inflammation","volume":"8","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116463","article-title":"Metabolic regulation of immunity in the tumor microenvironment","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0710","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0715","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41416-019-0644-x","article-title":"Energy metabolism manipulates the fate and function of tumour myeloid-derived suppressor cells","volume":"122","author":"Hu","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.intimp.2025.115948_bb0720","article-title":"The success of the tumor immunotherapy: neutrophils from bench to beside","volume":"24","author":"Zhu","year":"2025","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0725","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13045-021-01200-4","article-title":"Contradictory roles of lipid metabolism in immune response within the tumor microenvironment","volume":"6","author":"Yu","year":"2021","journal-title":"J. Hematol. OncolJ. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0730","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/biomedicines9040361","article-title":"The role of metabolism in tumor immune evasion: novel approaches to improve immunotherapy","volume":"9","author":"Cruz-Berm\u00fadez","year":"2021","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb0735","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3389\/fimmu.2018.02533","article-title":"Adenosinergic Signaling alters natural killer cell functional responses","volume":"30","author":"Chambers","year":"2018","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0740","article-title":"Adenosine, bridging chronic inflammation and tumor growth","volume":"31","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.intimp.2025.115948_bb0745","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/cells14141096","article-title":"The role of lactate in immune regulation: a metabolic rheostat via transporters, receptors, and epigenetic modifiers","volume":"14","author":"Choi","year":"2025","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.intimp.2025.115948_bb0750","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives","volume":"26","author":"Gu","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0755","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41392-022-01206-5","article-title":"Correction: lactate metabolism in human health and disease","volume":"31","author":"Li","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0760","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10565-025-10012-y","article-title":"Myeloid cells are involved in tumor immunity, metastasis and metabolism in tumor microenvironment","volume":"41","author":"Zhang","year":"2025","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0765","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0770","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-025-01038-9","article-title":"Arginine metabolism in myeloid cells in health and disease","volume":"47","author":"Karadima","year":"2025","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0775","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/imr.13215","article-title":"Lipid metabolism in dendritic cell biology","volume":"317","author":"You","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2025.115948_bb0780","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.freeradbiomed.2023.11.044","article-title":"In situ lipid-loading activates peripheral dendritic cell subsets characterized by cellular ROS accumulation but compromises their capacity to prime na\u00efve T cells","volume":"210","author":"Christ","year":"2024","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0785","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/ijms26072998","article-title":"PD-L1+ regulatory B cells from rheumatoid arthritis patients have impaired function in suppressing IFN-\u04af and IL-21 production","volume":"26","author":"Talib","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0790","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0795","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.apsb.2020.01.005","article-title":"A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses","volume":"10","author":"Zhai","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.intimp.2025.115948_bb0800","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0805","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0810","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s42003-024-06209-2","article-title":"Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen","volume":"7","author":"Zhang","year":"2024","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0815","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2025.115948_bb0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango?","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0825","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.intimp.2025.115948_bb0830","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.23.02314","article-title":"Safety and efficacy of CT041 in patients with refractory metastatic pancreatic Cancer: a pooled analysis of two early-phase trials","volume":"42","author":"Qi","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0835","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.1038\/s41467-024-53220-6","article-title":"PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial","volume":"15","author":"Stein","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0840","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neo.2021.12.005","article-title":"Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models","volume":"24","author":"Lee","year":"2022","journal-title":"Neoplasia N Y N."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0845","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0850","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb0855","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0860","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb0865","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb0870","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","article-title":"Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma","volume":"38","author":"Noel","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0875","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0880","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001006","article-title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","volume":"8","author":"Razak","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0885","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0890","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb0895","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/oncolo\/oyad022","article-title":"Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric Cancer: MORPHEUS phase Ib\/II umbrella randomized study platform","volume":"28","author":"Ko","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2025.115948_bb0900","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PANCA21-PR-002","article-title":"Abstract PR-002: A phase II pilot trial of nivolumab (N) + albumin bound paclitaxel (AP) + paricalcitol (P) + cisplatin (C) + gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC)","author":"Borazanci","year":"2021","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0905","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/annonc\/mds134","article-title":"VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA","volume":"23","author":"Martin","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb0910","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PANCA22-PR005","article-title":"Abstract PR005: primary results of PanCAN-SR1, a phase 1b study evaluating gemcitabine, nab-paclitaxel, canakinumab, and Spartalizumab to target IL-1\u03b2 and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis","author":"Oberstein","year":"2022","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.intimp.2025.115948_bb0915","doi-asserted-by":"crossref","first-page":"6293","DOI":"10.3390\/cancers13246293","article-title":"Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy","volume":"13","author":"Bullock","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb0920","first-page":"415","article-title":"Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I\/II trial","volume":"25","author":"Ogasawara","year":"2021","journal-title":"Ther. Apher. Dial Off. Peer-Rev. J. Int. Soc. Aph.er Jpn. Soc. Apher. Jpn. Soc. Dial. Ther."},{"issue":"18","key":"10.1016\/j.intimp.2025.115948_bb0925","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","article-title":"Results from a phase IIb, randomized, Multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study)","volume":"25","author":"Le","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0930","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41392-024-02031-8","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb0935","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic Cancer: the randomized phase II CISPD3 trial","volume":"30","author":"Fu","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb0940","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune Blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic adenocarcinoma","author":"Xie","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb0945","first-page":"1124","article-title":"Radiation therapy enhances immunotherapy response in microsatellite-stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat. Can."},{"issue":"17","key":"10.1016\/j.intimp.2025.115948_bb0950","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1158\/1078-0432.CCR-23-0535","article-title":"Treatment response in first-line metastatic pancreatic ductal adenocarcinoma is stratified by a composite index of tumor proliferation and CD8 T-cell infiltration","volume":"29","author":"Beatty","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0955","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","article-title":"A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors","volume":"71","author":"Raez","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"21","key":"10.1016\/j.intimp.2025.115948_bb0960","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.18632\/oncotarget.27586","article-title":"An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma","volume":"11","author":"Bever","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2025.115948_bb0965","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4172","article-title":"A phase I\/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC)","author":"Bajor","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb0970","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e16288","article-title":"A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma","author":"Yin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb0975","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-00872","article-title":"Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma","author":"Hammel","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2025.115948_bb0980","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant Selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with Resectable pancreatic Cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb0985","doi-asserted-by":"crossref","first-page":"73","DOI":"10.36401\/JIPO-23-16","article-title":"Phase Ib\/II study of Lacnotuzumab in combination with Spartalizumab in patients with advanced malignancies","volume":"7","author":"Ahmed","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0990","first-page":"119","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. CR."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb0995","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2054105","article-title":"STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer","volume":"11","author":"Da","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2025.115948_bb1000","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb1005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","article-title":"Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGF\u03b2 and activin a suppression","volume":"26","author":"Rea","year":"2025","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb1010","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","article-title":"Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Muthalagu","year":"2020","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb1015","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh4050","article-title":"Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8","volume":"8","author":"Walle","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb1020","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2025.115948_bb1025","doi-asserted-by":"crossref","first-page":"1104860","DOI":"10.3389\/fimmu.2023.1104860","article-title":"Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2025.115948_bb1030","article-title":"Dendritic cell-based immunotherapy in patients with resected pancreatic Cancer. J clin Oncol off J am soc","author":"FR","year":"2024","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-017-0459-2","article-title":"Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer","volume":"10","author":"Mehrotra","year":"2017","journal-title":"J. Hematol. OncolJ. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1040","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1038\/s41467-024-47949-3","article-title":"Macrophage-fibroblast JAK\/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer","volume":"15","author":"Raymant","year":"2024","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb1045","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3364","article-title":"SLC45A4 promotes glycolysis and prevents AMPK\/ULK1-induced autophagy in TP53 mutant pancreatic ductal adenocarcinoma","volume":"23","author":"Chen","year":"2021","journal-title":"J. Gene Med."},{"issue":"11","key":"10.1016\/j.intimp.2025.115948_bb1050","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.7150\/ijbs.60018","article-title":"Crosstalk between hypoxia-sensing ULK1\/2 and YAP-driven glycolysis fuels pancreatic ductal adenocarcinoma development","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1055","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","article-title":"GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency","volume":"15","author":"Guerrero","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40001-021-00567-x","article-title":"Dickkopf-related protein 3 alters aerobic glycolysis in pancreatic cancer BxPC-3 cells, promoting CD4+ T-cell activation and function","volume":"26","author":"Guo","year":"2021","journal-title":"Eur. J. Med. Res."},{"issue":"31","key":"10.1016\/j.intimp.2025.115948_bb1065","article-title":"Targeting the lactic acid metabolic pathway for antitumor therapy","volume":"19","author":"Li","year":"2023","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.intimp.2025.115948_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109521","article-title":"Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine","volume":"121","author":"Dai","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb1075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","article-title":"A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in Cancer cells","volume":"31","author":"Yoo","year":"2020","journal-title":"Cell Metab."},{"issue":"17","key":"10.1016\/j.intimp.2025.115948_bb1080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13048-024-01546-6","article-title":"Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors","volume":"14","author":"Udumula","year":"2024","journal-title":"J. Ovarian Res."},{"issue":"124","key":"10.1016\/j.intimp.2025.115948_bb1085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2019.10.020","article-title":"Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized phase IIb trial","volume":"1990","author":"Hammel","year":"2020","journal-title":"Eur. J. Cancer Oxf. Engl."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb1090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00262-024-03925-w","article-title":"IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization","volume":"74","author":"Guangzhao","year":"2025","journal-title":"Cancer Immunol. Immunother. CII."},{"key":"10.1016\/j.intimp.2025.115948_bb1095","article-title":"Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS-activated pancreatic cancer cells","volume":"61(3):108","author":"Terado","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb1100","article-title":"Amino acid metabolism in health and disease","volume":"13;8(1):345","author":"Ling","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"23","key":"10.1016\/j.intimp.2025.115948_bb1105","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12967-025-06664-3","article-title":"Branched-chain amino acid and cancer: metabolism, immune microenvironment and therapeutic targets","volume":"10","author":"Xiong","year":"2025","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb1110","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.apsb.2025.04.002","article-title":"Nanomedicine-driven tumor glucose metabolic reprogramming for enhanced cancer immunotherapy","volume":"15","author":"Jiang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2025.115948_bb1115","article-title":"Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis","volume":"23","author":"Parveen","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.intimp.2025.115948_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.fmre.2024.09.011","article-title":"Targeting fatty acid metabolism for cancer therapy","author":"Zhang","year":"2024","journal-title":"Fundam Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1125","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1186\/s12967-024-05598-6","article-title":"Fatty acid oxidation is critical for the tumorigenic potential and chemoresistance of pancreatic cancer stem cells","volume":"22","author":"Mascaraque","year":"2024","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2025.115948_bb1130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2024.04.007","article-title":"Emerging targets in lipid metabolism for cancer therapy","volume":"45","author":"Terry","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb1135","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/molecules30030654","article-title":"Epigallocatechin gallate (EGCG): pharmacological properties, biological activities and therapeutic potential","volume":"30","author":"Capasso","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2025.115948_bb1140","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3426902","article-title":"3\u03b2-hydroxysteroid-\u039424 reductase (DHCR24) protects pancreatic \u03b2 cells from endoplasmic reticulum stress-induced apoptosis by scavenging excessive intracellular reactive oxygen species","volume":"2020","author":"Li","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb1145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/biom14040410","article-title":"Chemical inhibition of sterol biosynthesis","volume":"14","author":"Peeples","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.intimp.2025.115948_bb1150","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.3390\/ijms25073874","article-title":"Squalene epoxidase: its regulations and links with cancers","volume":"25","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb1155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","article-title":"LXR\/ApoE activation restricts innate immune suppression in cancer","volume":"172","author":"Tavazoie","year":"2018","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb1160","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/ph13120422","article-title":"Statins: HMG-CoA reductase inhibitors as potential anticancer agents against malignant neoplasms in women","volume":"13","author":"Markowska","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb1165","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1172\/JCI124077","article-title":"IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma","volume":"129","author":"Blair","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.intimp.2025.115948_bb1170","article-title":"Arginase 1 is a key driver of immune suppression in pancreatic cancer","volume":"2","author":"Menjivar","year":"2023","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb1175","first-page":"611","article-title":"Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1\/PD-L1 treatment","volume":"6","author":"Laubach","year":"2023","journal-title":"Cancer Drug Resist. Alhambra. Calif."},{"key":"10.1016\/j.intimp.2025.115948_bb1180","article-title":"Adenosinergic axis and immune checkpoint combination therapy in tumor: a new perspective for immunotherapy strategy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40364-025-00784-0","article-title":"The progress and prospects of targeting the adenosine pathway in cancer immunotherapy","volume":"13","author":"Yang","year":"2025","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb1190","first-page":"448","article-title":"The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2","volume":"5","author":"Chaib","year":"2024","journal-title":"Nat. Can."},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb1195","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001367","article-title":"Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis","volume":"8","author":"Ho","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1200","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"13","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2025.115948_bb1205","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/ijms22042091","article-title":"Ablative radiotherapy reprograms the tumor microenvironment of a pancreatic tumor in Favoring the immune checkpoint blockade therapy","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb1210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41416-018-0281-9","article-title":"A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours","volume":"119","author":"Maity","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2025.115948_bb1215","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/1078-0432.CCR-19-2078","article-title":"Pembrolizumab in combination with the oncolytic virus Pelareorep and chemotherapy in patients with advanced pancreatic adenocarcinoma: a phase Ib study","volume":"26","author":"Mahalingam","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"34","key":"10.1016\/j.intimp.2025.115948_bb1225","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2023.09.2572","article-title":"1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: results from the GOBLET study","volume":"1","author":"Arnold","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115948_bb1230","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"14","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"issue":"7963","key":"10.1016\/j.intimp.2025.115948_bb1235","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2025.115948_bb1240","volume":"41(4_suppl):TPS761\u2013TPS761","author":"Bai","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2025.115948_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-\u03b2 receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115948_bb1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-\u03b2 receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.intimp.2025.115948_bb1255","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.intimp.2025.115948_bb1260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumor progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2025.115948_bb1265","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1551322","article-title":"IFN-\u03b3-mediated suppression of ANGPT2-Tie2 in endothelial cells facilitates tumor vascular normalization during immunotherapy","volume":"16","author":"Cai","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb1270","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2025.115948_bb1275","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10555-021-09981-3","article-title":"Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance","volume":"40","author":"Heumann","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.intimp.2025.115948_bb1280","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"18;23(1):203","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2025.115948_bb1285","article-title":"mTOR-mediated regulation of immune responses in Cancer and tumor microenvironment","volume":"12","author":"Mafi","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2025.115948_bb1290","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41589-022-01017-3","article-title":"Lipid metabolism in T cell signaling and function","volume":"18","author":"Lim","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.intimp.2025.115948_bb1295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/apc.2020.03.03","article-title":"Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma","volume":"3","author":"He","year":"2020","journal-title":"Ann. Pancreat. Cancer."},{"issue":"28","key":"10.1016\/j.intimp.2025.115948_bb1300","article-title":"A review of emerging biomarkers for immune checkpoint inhibitors in Tumors of the gastrointestinal tract","volume":"5","author":"Liao","year":"2022","journal-title":"Med Sci Monit Int Med J Exp Clin Res."},{"issue":"9","key":"10.1016\/j.intimp.2025.115948_bb1305","first-page":"2446","article-title":"Diagnostic bioliquid markers for pancreatic Cancer: what we have vs","volume":"15","author":"Liou","year":"2023","journal-title":"What We Need. Cancers."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925019368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T16:07:25Z","timestamp":1768061245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925019368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":261,"alternative-id":["S1567576925019368"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115948","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor microenvironment and immunometabolic reprogramming in pancreatic ductal adenocarcinoma: Barriers and breakthroughs in immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115948"}}